Colour guide to the snakes of Sri Lanka: De Silva, A. Avon: R & A Publishing (1990)Toxicon1992PDF74 KB
Quality of life in multiple sclerosis: influence of interferon-β1a (Avonex®) treatmentVermersch · Multiple Sclerosis Journal2002PDF183 KB
Selective immune activation following initiation of IFN-β 1a (AVONEXTM) therapyBoylan · Journal of Neuroimmunology1998PDF121 KB
A randomized, controlled trial of interferon-β-1a (Avonex®) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]Genovese et al. · BioMed Central2004PDF62 KB
Pharmacological and clinical profile of IFNβ-1a (Avonex®IM Injection Syringe 30μg)Sumino · Japan Science and Technology Information Aggregator, Electronic2007PDF1.1 MB
Extended observations on MS patients treated with IM interferon-β1a (AvonexTM): implications for modern MS trials and therapeuticsJacobs · Journal of Neuroimmunology2000PDF80 KB
Interferon β1a (Avonex®) treatment in multiple sclerosis: similarity of effect on progression of disability in patients with mild and moderate disabilityVermersch · Journal of Neurology2002PDF269 KB
Neutralizing Antibodies to Interferon β-1a (IFNβ-1a; Avonex™) and Interferon β-1b (IFN β-1b; Betaseron®) are Cross ReactiveKhan · Neurology1998PDF343 KB
A prospective, open-label treatment trial to compare the effect of IFN β-1a (Avonex), IFNβ-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosisKhan · European Journal of Neurology2001PDF166 KB
Posterior urethral injuries in children: A. Avonglu, I. Ulman, Ö. Herek, et al. Br J Urol 77:597–600, (April), 1996Hunt · Journal of Pediatric Surgery1997PDF145 KB
Phase III SUNBEAM and RADIANCE PART B trials for Ozanimod in relapsing multiple sclerosis demonstrate superiority versus interferon-β-1a (Avonex ® ) in reducing annualized relapse rates and MRI brain lesionsKoscielny · Future Medicine2018PDF715 KB
